Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Stomach Neoplasms 2Recurrence 2Neoplasms 2Lymphoma 2Small Cell Lung Carcinoma 1Melanoma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1COVID-19 1Advanced Solid Tumors 1Advanced Solid Malignancies 1

Interventions

ofatumumab 10ibrutinib 6Rituximab 5acalabrutinib 4Cyclophosphamide 3spebrutinib 2pirtobrutinib 2obinutuzumab 2navitoclax 2fludarabine phosphate 2Tablets 2Lenalidomide 2KW-2478 2Chlorambucil 2Antigens, CD19 2ARQ531 2venetoclax 1tirabrutinib 1pomalidomide 1pivalyloxymethyl butyrate 1immunotoxin HA22 1idelalisib 1idecabtagene vicleucel 1fludarabine 1dinaciclib 1bempegaldesleukin 1Vincristine 1Rabeprazole 1Prednisone 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, B-Cell × Rabeprazole × Clear all
NCT06787131 2025-12-05

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Lomond Therapeutics Holdings, Inc.

Phase 1 Completed
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡